Statements (24)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:activeIngredient |
gptkb:vandetanib
|
| gptkbp:approvalYear |
2011
|
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA |
| gptkbp:ATCCode |
L01XE12
|
| https://www.w3.org/2000/01/rdf-schema#label |
Caprelsa
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Sanofi_Genzyme
|
| gptkbp:mechanismOfAction |
gptkb:receptor_tyrosine_kinase
|
| gptkbp:pregnancyCategory |
D (US)
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
diarrhea
fatigue hypertension rash QT prolongation |
| gptkbp:target |
gptkb:EGFR
gptkb:VEGFR gptkb:RET |
| gptkbp:usedFor |
medullary thyroid cancer
|
| gptkbp:bfsParent |
gptkb:vandetanib
gptkb:赛诺菲 |
| gptkbp:bfsLayer |
6
|